| Inclusion Criteria: | Patients must have histologiclly proven Stage IVB, recurrent or persistent Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy.
All patients must have measurable disease. See protocol for description of "measurable disease".
Patients must have adequate Hematologic function: ANC equal to or greater than 1500/ul- platelets equal to or greater than 100,000/ul.
Patients must have adequate hepatic function. Bilirubin equal to or less than 1.5 x institutional normal- SGOT, alkaline pphosphatase equal to or less than 3x institutional normal.
Patients must have a GOG Performance Status of 0 or 1.
Patients must have recovered from the effects of surgery, radiation therapy or chemoradiotherapy. At least six weeks must have elapsed from the last administration of chemoradiotherapy, and at least three weeks must have elapsed from the last administration of radiation therapy alone.
Patients must meet all of the pre-entry requirements specified in Section 7.0 of the protocol including baseline QOL questionnaire.
Patients must be free of clinically significant infection.
Patients must have signed an approved informed consent and authorization permitting release of personal health information.
Patients must have adequate Renal function. Serum creatinine less than or equal to 1.2 mg/dl. Pts. with a serum creatinine greater than 1.2 mg/dl but less than 1.5 mg/dl must have a 24-hour creatinine clearance determination of greater than or equal to 50cc/min to be eligible. |